Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also operates through SecureDose Synthetics Inc., which is a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.


CSE:PHRX - Post by User

Comment by SamRothsteinon Jan 05, 2021 4:25pm
70 Views
Post# 32226259

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:4 out of 5 predictions from Lowfloat are absolute disasters

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:4 out of 5 predictions from Lowfloat are absolute disastersAs I said, we are going to have to agree to disagree on Booth.  Booth is a deal maker. That is exactly what you want in a new sector.  If you look at Canopy's first year as publicly traded company you will see how little they actually had, and how fast they grew, fuelled by private placements and deals.  I'm not saying BUZZ is next canopy.  I'm saying this is a new sector and deal making experience and finess are going to be critial.  It is exactly why i am super bullish on TRIP, as I think Linton is better than Booth.  I have said it before but i wouldn't even own my BUZZ shares right now if it weren't for all the TRIP shares and warrants they have.  Bottom line, if you think have Terry is a net negative that is your opinion, and we have already conclusively established what your opinion is worth.  

Lowfloatmining1 wrote:

Yes the entire sector was pumped then dumped! It's still going down some look at the trend. We can agree it's in a downtrend. 

Of course a private placement for more would be good but get real that's not how big fish get rich. They pay less all at the expense of current share holders. 

You compare buzz to canopy come on now.  Canopy is and was a giant to begin with in a much broader cannabis market.  

Terry Booth is NOT a good advisor.  You trash my track record yet promote Booth who screwed up Acb to the point that shareholders will never break even.  Dilution after dilution all while in the growth stage which ended up with millions of write downs.  Save yourself the trouble of spinning Booth in a positive way because he isn't! 

 



<< Previous
Bullboard Posts
Next >>